立方制药(003020) - 2021 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2021 reached ¥591,088,785.10, representing a year-on-year increase of 22.09%[3] - Net profit attributable to shareholders was ¥41,758,248.46, up 24.22% compared to the same period last year[3] - The net profit excluding non-recurring gains and losses was ¥37,487,510.07, reflecting a 22.92% increase year-on-year[3] - Total operating revenue for the current period reached ¥1,664,897,737.44, an increase of 21.0% compared to ¥1,376,200,536.00 in the previous period[19] - Net profit for the current period was ¥125,342,624.90, representing a 25.8% increase from ¥99,662,537.09 in the same period last year[21] - Total comprehensive income for the current period was ¥125,342,624.90, compared to ¥99,662,537.09 in the previous period[21] - Basic and diluted earnings per share were both ¥1.3530, slightly down from ¥1.4344 in the previous period[21] Assets and Liabilities - Total assets at the end of Q3 2021 amounted to ¥1,770,186,835.15, a 15.25% increase from the end of the previous year[3] - As of September 30, 2021, total assets amounted to CNY 1,770,186,835.15, an increase from CNY 1,536,019,607.62 at the end of 2020, representing a growth of approximately 15.2%[16] - The total liabilities rose to CNY 517,171,079.22 from CNY 362,026,476.59, marking an increase of about 43.0%[17] - Total liabilities increased from 362,026,476.59 to 382,768,647.30, marking a rise of approximately 5.9%[28] - Current liabilities totaled 342,348,403.07, unchanged from the previous period[28] Cash Flow and Investments - The company's cash flow from operating activities showed a net decrease of 24.64% year-to-date, totaling ¥116,367,931.67[3] - Cash flow from operating activities generated a net amount of ¥116,367,931.67, down 24.7% from ¥154,412,593.92 in the prior period[24] - The company experienced a net cash outflow from investing activities of ¥564,305,404.62, compared to a smaller outflow of ¥33,813,540.75 in the prior period[24] - The net increase in cash and cash equivalents was -¥507,697,451.75, a decrease of 1073.96% due to increased investments in structured deposits and long-term assets[9] - The company reported a significant cash inflow of ¥1,075,000,000.00 from other investment activities during the current period[24] Accounts Receivable and Inventory - The company reported a significant increase in accounts receivable by 66.04%, reaching ¥390,296,492.65, due to new sales and extended credit terms[7] - Accounts receivable increased significantly to CNY 390,296,492.65 from CNY 235,059,021.75, reflecting a growth of approximately 66.1%[15] - The company’s inventory increased to CNY 217,968,090.38 from CNY 193,799,902.99, representing a rise of approximately 12.4%[15] - The company’s inventory was reported at 193,799,902.99, maintaining operational efficiency[26] Corporate Governance and Strategic Initiatives - The company appointed a new non-independent director and vice general manager, Wang Qing, to enhance corporate governance[13] - The company made a strategic investment of ¥20,000,000.00 in Nanjing Mainowei Pharmaceutical Technology Co., Ltd[9] - The company received approval for the raw material drug methylphenidate hydrochloride and obtained a drug registration certificate for sustained-release tramadol tablets, enhancing its product pipeline[13] - The company reported no violations regarding external guarantees or non-operating fund occupation by controlling shareholders during the reporting period[13] Research and Development - Research and development expenses increased to ¥42,897,403.88, up 27.2% from ¥33,720,047.12 in the previous period[20] Equity and Ownership - The company’s total equity attributable to shareholders increased to CNY 1,253,015,755.93 from CNY 1,173,993,131.03, reflecting a growth of about 6.8%[17] - Owner's equity remained constant at 1,173,993,131.03, indicating no change in shareholder equity[28]